Establishing an EGFR mutation screening service for non-small cell lung cancer - sample quality criteria and candidate histological predictors.

摘要: Abstract Introduction EGFR screening requires good quality tissue, sensitivity and turn-around time (TAT). We report our experience of routine screening, describing sample type, TAT, specimen (cellularity DNA yield), histopathological description, mutation result clinical outcome. Methods Non-small cell lung cancer (NSCLC) sections were screened for mutations (M+) in exons 18–21. Clinical, pathological outcome data collected year 1 testing. Screening alone was 2. Results In 1, 152 samples tested, most (72%) diagnostic. TAT 4.9days (95%confidence interval (CI)=4.5–5.5). -M+ prevalence 11% higher (20%) among never-smoking women with adenocarcinomas (ADCs), but 30% occurred current/ex-smoking men. tumours non-mucinous ADCs 100% thyroid transcription factor (TTF1+). No detected poorly differentiated NSCLC-not otherwise specified (NOS). There a trend improved overall survival (OS) versus -M– patients (median OS=78 17months). test failure rate 19%, associated scant cellularity low concentrations. However 75% poor representative tumour informative 9%. 2, 755 tested; 13% only 5.4%. Although concentration ( 2.2ng/μL), the 9.2%. Conclusion Routine epidermal growth receptor ) using diagnostic is fast feasible even on content. Mutations tend to occur better-differentiated TTF1+ ADCs. Whether these histological criteria may be useful select testing merits further investigation.